JP2014156468A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014156468A5 JP2014156468A5 JP2014075501A JP2014075501A JP2014156468A5 JP 2014156468 A5 JP2014156468 A5 JP 2014156468A5 JP 2014075501 A JP2014075501 A JP 2014075501A JP 2014075501 A JP2014075501 A JP 2014075501A JP 2014156468 A5 JP2014156468 A5 JP 2014156468A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- medicament
- treatment
- compound selected
- dimethoxyphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- IRBAWVGZNJIROV-SFHVURJKSA-N 9-(2-cyclopropylethynyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC4CC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 IRBAWVGZNJIROV-SFHVURJKSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- SIKXWJFYMYNNGL-UHFFFAOYSA-N n-(3,4-dimethoxyphenyl)-4-oxo-1h-quinoline-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1NC(=O)C1=CNC2=CC=CC=C2C1=O SIKXWJFYMYNNGL-UHFFFAOYSA-N 0.000 claims 1
Description
Claims (3)
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58267604P | 2004-06-24 | 2004-06-24 | |
US60/582,676 | 2004-06-24 | ||
US63012704P | 2004-11-22 | 2004-11-22 | |
US60/630,127 | 2004-11-22 | ||
US63567404P | 2004-12-13 | 2004-12-13 | |
US60/635,674 | 2004-12-13 | ||
US65821905P | 2005-03-03 | 2005-03-03 | |
US60/658,219 | 2005-03-03 | ||
US66131105P | 2005-03-11 | 2005-03-11 | |
US60/661,311 | 2005-03-11 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012050845A Division JP2012107069A (ja) | 2004-06-24 | 2012-03-07 | Atp結合カセットトランスポーターのモジュレーター |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015135324A Division JP2015172087A (ja) | 2004-06-24 | 2015-07-06 | Atp結合カセットトランスポーターのモジュレーター |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014156468A JP2014156468A (ja) | 2014-08-28 |
JP2014156468A5 true JP2014156468A5 (ja) | 2015-08-20 |
Family
ID=35429349
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007518350A Active JP4947658B2 (ja) | 2004-06-24 | 2005-06-24 | Atp結合カセットトランスポーターのモジュレーター |
JP2011266326A Active JP5654979B2 (ja) | 2004-06-24 | 2011-12-05 | Atp結合カセットトランスポーターのモジュレーター |
JP2011266327A Active JP5712117B2 (ja) | 2004-06-24 | 2011-12-05 | Atp結合カセットトランスポーターのモジュレーター |
JP2011266325A Active JP5762940B2 (ja) | 2004-06-24 | 2011-12-05 | Atp結合カセットトランスポーターのモジュレーター |
JP2012050845A Pending JP2012107069A (ja) | 2004-06-24 | 2012-03-07 | Atp結合カセットトランスポーターのモジュレーター |
JP2014075501A Ceased JP2014156468A (ja) | 2004-06-24 | 2014-04-01 | Atp結合カセットトランスポーターのモジュレーター |
JP2015135324A Withdrawn JP2015172087A (ja) | 2004-06-24 | 2015-07-06 | Atp結合カセットトランスポーターのモジュレーター |
JP2016247687A Active JP6285004B2 (ja) | 2004-06-24 | 2016-12-21 | Atp結合カセットトランスポーターのモジュレーター |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007518350A Active JP4947658B2 (ja) | 2004-06-24 | 2005-06-24 | Atp結合カセットトランスポーターのモジュレーター |
JP2011266326A Active JP5654979B2 (ja) | 2004-06-24 | 2011-12-05 | Atp結合カセットトランスポーターのモジュレーター |
JP2011266327A Active JP5712117B2 (ja) | 2004-06-24 | 2011-12-05 | Atp結合カセットトランスポーターのモジュレーター |
JP2011266325A Active JP5762940B2 (ja) | 2004-06-24 | 2011-12-05 | Atp結合カセットトランスポーターのモジュレーター |
JP2012050845A Pending JP2012107069A (ja) | 2004-06-24 | 2012-03-07 | Atp結合カセットトランスポーターのモジュレーター |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015135324A Withdrawn JP2015172087A (ja) | 2004-06-24 | 2015-07-06 | Atp結合カセットトランスポーターのモジュレーター |
JP2016247687A Active JP6285004B2 (ja) | 2004-06-24 | 2016-12-21 | Atp結合カセットトランスポーターのモジュレーター |
Country Status (26)
Country | Link |
---|---|
US (14) | US7495103B2 (ja) |
EP (6) | EP2530075A3 (ja) |
JP (8) | JP4947658B2 (ja) |
CN (6) | CN101891680B (ja) |
AU (4) | AU2005258320B2 (ja) |
BR (2) | BRPI0511321B8 (ja) |
CA (3) | CA2571949C (ja) |
CY (4) | CY1116116T1 (ja) |
DK (3) | DK2489659T3 (ja) |
ES (4) | ES2534606T3 (ja) |
HK (4) | HK1105970A1 (ja) |
HR (3) | HRP20150277T1 (ja) |
HU (3) | HUE032540T2 (ja) |
IL (9) | IL180224A (ja) |
LT (3) | LT2489659T (ja) |
LU (1) | LU92761I2 (ja) |
ME (3) | ME02156B (ja) |
MX (3) | MX2007000095A (ja) |
NL (1) | NL300748I1 (ja) |
NZ (6) | NZ587547A (ja) |
PL (3) | PL1773816T3 (ja) |
PT (3) | PT2502911T (ja) |
RS (3) | RS56873B1 (ja) |
SI (1) | SI2489659T1 (ja) |
WO (1) | WO2006002421A2 (ja) |
ZA (1) | ZA200700601B (ja) |
Families Citing this family (247)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
MXPA06002567A (es) | 2003-09-06 | 2006-09-04 | Vertex Pharma | Moduladores de transportadores con casete de union de atp. |
EP1682127B1 (en) * | 2003-11-14 | 2009-07-29 | Vertex Pharmaceuticals Incorporated | Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters |
US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
NZ587547A (en) * | 2004-06-24 | 2012-09-28 | Vertex Pharma | Modulators of ATP-Binding Cassette Transporters |
US20140343098A1 (en) * | 2004-06-24 | 2014-11-20 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
US8354427B2 (en) * | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
ES2431050T3 (es) | 2005-08-04 | 2013-11-22 | Sirtris Pharmaceuticals, Inc. | Benzotiazoles y tiazolopiridinas como moduladores de la sirtuína |
US8093401B2 (en) * | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
US7855289B2 (en) * | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
US8088928B2 (en) * | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
NZ566208A (en) | 2005-08-11 | 2010-09-30 | Vertex Pharma | 2-Thiazolamide derivatives as modulators of cystic fibrosis transmembrane conductance regulators |
SI2404919T1 (sl) | 2005-11-08 | 2013-12-31 | Vertex Pharmaceuticals Incorporated | Heterocikliäśna spojina uporabna kot modulator za prenaĺ alce z atp-vezavno kaseto |
AU2006322094A1 (en) | 2005-12-08 | 2007-06-14 | Millennium Pharmaceuticals, Inc. | Bicyclic compounds with kinase inhibitory activity |
US20090105272A1 (en) * | 2005-12-24 | 2009-04-23 | Grootenhuis Peter D J | Prodrugs of modulators of ABC transporters |
EP1974212A1 (en) * | 2005-12-27 | 2008-10-01 | Vertex Pharmaceuticals Incorporated | Compounds useful in cftr assays and methods therewith |
PL3219705T3 (pl) * | 2005-12-28 | 2020-08-10 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne amorficznych postaci n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4-dihydro-4-oksochinolino-3-karboksyamidu |
AU2016219571B2 (en) * | 2005-12-28 | 2018-03-15 | Vertex Pharmaceuticals Incorporated | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
US7671221B2 (en) * | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
AU2013201426B2 (en) * | 2005-12-28 | 2016-06-02 | Vertex Pharmaceuticals Incorporated | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
ES2398319T3 (es) | 2005-12-28 | 2013-03-15 | Vertex Pharmaceuticals Incorporated | Derivados de 1-(benzo[D][1,3]dioxol-5-il)-N-(fenil)ciclopropano-carboxamida y compuestos relacionados como moduladores de transportadores de casetes de unión a ATP para el tratamiento de la fibrosis quística |
US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
SI3091011T1 (en) | 2006-04-07 | 2018-06-29 | Vertex Pharmaceuticals Incorporated | Modulators of ATP conveyor belt conveyors |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
ATE534383T1 (de) * | 2006-05-12 | 2011-12-15 | Vertex Pharma | Zusammensetzungen aus n-ä2,4-bis(1,1- dimethylethyl)-5-hydroxyphenylü-1,4-dihydro-4- oxochinolin-3-carboxamid |
JPWO2008053764A1 (ja) * | 2006-10-30 | 2010-02-25 | 公立大学法人名古屋市立大学 | 抗プリオン活性化合物、抗プリオン活性剤及び異常型プリオンタンパク質生成の阻害方法 |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
US8283351B2 (en) * | 2007-04-02 | 2012-10-09 | Institute For Oneworld Health | Cyclic and acyclic hydrazine derivatives compositions including them and uses thereof |
CA2687715A1 (en) * | 2007-05-09 | 2008-11-20 | Traffick Therapeutics Inc. | Screening assay to identify correctors of protein trafficking defects |
AU2008251504B2 (en) | 2007-05-09 | 2013-07-18 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
WO2008147952A1 (en) * | 2007-05-25 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US8003692B2 (en) * | 2007-06-15 | 2011-08-23 | Board Of Regents, The University Of Texas System | Methods and compositions to inhibit edema factor and adenylyl cyclase |
CL2008001822A1 (es) * | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras. |
WO2009023509A2 (en) * | 2007-08-09 | 2009-02-19 | Vertex Pharmaceuticals Incorporated | Therapeutic combinations useful in treating cftr related diseases |
NZ583420A (en) * | 2007-08-24 | 2012-06-29 | Vertex Pharma | Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis |
EP2201010B1 (en) | 2007-09-14 | 2013-11-06 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
CN101918366A (zh) * | 2007-09-14 | 2010-12-15 | 弗特克斯药品有限公司 | N-[2,4-双(1,1-二甲基乙基)-5-羟基苯基]-1,4-二氢-4-氧代喹啉-3-甲酰胺的固体形式 |
AU2008312653B2 (en) * | 2007-10-19 | 2013-03-07 | Janssen Pharmaceutica, N.V. | Amide linked modulators of y-secretase |
KR20100092000A (ko) * | 2007-11-01 | 2010-08-19 | 서트리스 파마슈티컬즈, 인코포레이티드 | 시르투인 조절제로서의 아미드 유도체 |
BRPI0820377A2 (pt) * | 2007-11-08 | 2015-05-19 | Sirtris Pharmaceutical Inc | Tiazolopiridinas solubilizadas |
EP2217572B1 (en) * | 2007-11-16 | 2013-11-06 | Vertex Pharmaceuticals Incorporated | Isoquinoline modulators of atp-binding cassette transporters |
US20100036130A1 (en) * | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
KR20150063170A (ko) | 2007-12-07 | 2015-06-08 | 버텍스 파마슈티칼스 인코포레이티드 | 3-(6-(1-(2,2-디플루오로벤조[d][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태 |
EA201070699A1 (ru) * | 2007-12-07 | 2011-02-28 | Вертекс Фармасьютикалз Инкорпорейтед | Композиции 3-(6-(1-2,2-дифторбензо[d][1,3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты |
DK2639222T3 (en) | 2007-12-07 | 2016-10-03 | Vertex Pharma | Methods for preparing cycloalkylcarboxamido-pyridinbenzoesyrer |
CN101925603B (zh) * | 2007-12-13 | 2013-12-04 | 沃泰克斯药物股份有限公司 | 囊性纤维化跨膜通道调节因子的调节剂 |
NZ602030A (en) | 2008-02-28 | 2014-02-28 | Vertex Pharma | Heteroaryl derivatives as cftr modulators |
CN103951614A (zh) | 2008-03-31 | 2014-07-30 | 沃泰克斯药物股份有限公司 | 作为cftr调节剂的吡啶基衍生物 |
WO2009131954A2 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising oxadiazole derivatives |
WO2009131952A1 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising thiazole derivatives |
EP2278879B1 (en) | 2008-04-21 | 2016-06-15 | PATH Drug Solutions | Compounds, compositions and methods comprising oxadiazole derivatives |
WO2009131948A2 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | High-throughput cell-based cftr assay |
WO2009131958A2 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising triazine derivatives |
WO2009131947A2 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyridazine derivatives |
WO2009131956A1 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising triazole derivatives |
WO2009131951A2 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising isoxazole derivatives |
US20100256184A1 (en) * | 2008-08-13 | 2010-10-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
EP2341776A4 (en) * | 2008-09-19 | 2012-05-30 | Inst Oneworld Health | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING IMIDAZOL AND TRIAZOL DERIVATIVES |
AR073709A1 (es) * | 2008-09-29 | 2010-11-24 | Vertex Pharma | Unidades de dosis de acido 3-(6-(1-(2,2-difluorobenzeno (d) (1,3) dioxol-5-il) ciclopropancarboxamido)-3-metilpiridin-2-il) benzoico |
NZ592687A (en) * | 2008-10-23 | 2013-04-26 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
AR074060A1 (es) * | 2008-10-23 | 2010-12-22 | Vertex Pharma | Moduladores del regulador de conductancia transmembrana de la fibrosis quistica |
AU2009308241B2 (en) * | 2008-10-23 | 2016-01-07 | Vertex Pharmaceuticals Incorporated | Solid forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl) phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide |
UA104876C2 (uk) * | 2008-11-06 | 2014-03-25 | Вертекс Фармасьютікалз Інкорпорейтед | Модулятори atф-зв'язувальних касетних транспортерів |
ES2532753T3 (es) | 2008-11-06 | 2015-03-31 | Vertex Pharmaceuticals Incorporated | Moduladores de transportadores del casete de unión a ATP |
UA104447C2 (uk) | 2008-12-19 | 2014-02-10 | Сіртріз Фармасьютікалз, Інк. | Тіазолопіридинові сполуки, що модулюють сиртуїн |
US8367660B2 (en) | 2008-12-30 | 2013-02-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
TWI461197B (zh) * | 2009-03-12 | 2014-11-21 | 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier | |
PL2408749T3 (pl) * | 2009-03-20 | 2018-11-30 | Vertex Pharmaceuticals Incorporated | Modulatory transbłonowego regulatora przewodnictwa mukowiscydozy |
NZ624460A (en) | 2009-03-20 | 2015-12-24 | Vertex Pharma | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
US8511216B2 (en) * | 2009-03-30 | 2013-08-20 | Kanzaki Kokyukoki Mfg. Co., Ltd. | Hydraulic actuator unit |
US8343976B2 (en) * | 2009-04-20 | 2013-01-01 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyrazole derivatives |
EP2266562A1 (en) * | 2009-06-23 | 2010-12-29 | Centre National de la Recherche Scientifique | Use of derivatives of indoles for the treatment of cancer |
US8703808B2 (en) | 2009-06-23 | 2014-04-22 | Centre National De La Recherche Scientifique | Use of derivatives of indoles for the treatment of cancer |
JP5793496B2 (ja) * | 2009-09-17 | 2015-10-14 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | アザ二環式化合物を調製するプロセス |
EP2490687A1 (en) * | 2009-10-22 | 2012-08-29 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
RU2568608C2 (ru) * | 2009-10-23 | 2015-11-20 | Вертекс Фармасьютикалз Инкорпорейтед | Твердые формы n-(4-(7-азабицикло[2.2.1]гептан-7-ил)-2-(трифторметил)фенил)-4-оксо-5-(трифторметил)-1,4-дигидрохинолин-3-карбоксамида |
CN102648182A (zh) * | 2009-10-23 | 2012-08-22 | 沃泰克斯药物股份有限公司 | 用于制备囊性纤维化跨膜传导调节因子的调节剂的方法 |
WO2011069298A1 (en) * | 2009-12-11 | 2011-06-16 | F. Hoffmann-La Roche Ag | Novel cyclopropane indolinone derivatives |
CN103180298A (zh) * | 2010-03-19 | 2013-06-26 | 沃泰克斯药物股份有限公司 | N-[2,4-双(1,1-二甲基乙基)-5-羟基苯基]-1,4-二氢-4-氧代喹啉-3-甲酰胺的固体形式 |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
SG184156A1 (en) * | 2010-04-02 | 2012-10-30 | Senomyx Inc | Sweet flavor modifier |
HUE056525T2 (hu) | 2010-04-07 | 2022-02-28 | Vertex Pharma | 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)ciklopropánkarboxamido)-3-metilpiridin-2-il)benzoesav gyógyszerészeti készítményei és azok adagolása |
RU2579370C2 (ru) | 2010-04-07 | 2016-04-10 | Вертекс Фармасьютикалз Инкорпорейтед | Твердые формы 3-(2, 2-дифторбензо[d][1, 3] диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты |
NZ603042A (en) | 2010-04-22 | 2015-02-27 | Vertex Pharma | Pharmaceutical compositions comprising cftr modulators and administrations thereof |
EP2560651A1 (en) | 2010-04-22 | 2013-02-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
MX353408B (es) | 2010-04-22 | 2018-01-11 | Vertex Pharma | Proceso para producir compuestos de cicloalquilcarboxamido-indol. |
EP2560650A1 (en) | 2010-04-22 | 2013-02-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
AR081920A1 (es) | 2010-05-20 | 2012-10-31 | Vertex Pharma | Procesos de produccion de moduladores del regulador de conductancia transmembrana de fibrosis quistica |
US20110288122A1 (en) | 2010-05-20 | 2011-11-24 | Vertex Pharmaceuticals Incorporated | Pharmaceutical Compositions and Administrations Thereof |
US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
JP5525612B2 (ja) * | 2010-07-23 | 2014-06-18 | 国立大学法人 東京大学 | 含窒素複素環誘導体 |
AU2015201412A1 (en) * | 2010-09-14 | 2015-04-02 | Instytut Biochemii I Biofizyki Pan | Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction |
NZ609204A (en) * | 2010-09-14 | 2015-05-29 | Inst Biochemii I Biofizyki Pan | Compounds as modulators of a mutant cftr protein and their use for treating diseases associated with cftr protein malfunction |
US8802700B2 (en) * | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
HUE047354T2 (hu) | 2011-05-18 | 2020-04-28 | Vertex Pharmaceuticals Europe Ltd | Ivacaftor deuterizált származékai |
EP2709986B1 (en) * | 2011-05-18 | 2017-03-22 | Concert Pharmaceuticals Inc. | Deuterated derivatives of ivacaftor |
CN102816175B (zh) * | 2011-06-09 | 2015-12-16 | 上海汇伦生命科技有限公司 | 一种杂环并吡啶酮类化合物,其中间体、制备方法和用途 |
CA2841012C (en) | 2011-08-12 | 2019-07-30 | Senomyx, Inc. | Sweet flavor modifier |
EP2773349A1 (en) | 2011-11-02 | 2014-09-10 | Vertex Pharmaceuticals Incorporated | Use of (n- [2, 4 -bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl]- 1, 4 - dihydro - 4 - oxoquinoline - 3 - carboxamide) for treating cftr mediated diseases |
RU2640420C2 (ru) | 2011-11-08 | 2018-01-09 | Вертекс Фармасьютикалз Инкорпорейтед | Модуляторы транспортеров атф-связывающей кассеты |
IL265430B1 (en) | 2012-02-27 | 2024-04-01 | Vertex Pharma | Pharmaceutical preparations containing a solid dispersion of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide and uses thereof |
US8674108B2 (en) | 2012-04-20 | 2014-03-18 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
CA2869847A1 (en) | 2012-04-20 | 2013-10-24 | Vertex Pharmaceuticals Incorporated | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
CA2874851A1 (en) | 2012-06-08 | 2013-12-12 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cftr-mediated disorders |
AU2013290444B2 (en) | 2012-07-16 | 2018-04-26 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof |
US10092574B2 (en) | 2012-09-26 | 2018-10-09 | Valorisation-Recherche, Limited Partnership | Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof |
EP2914248B2 (en) | 2012-11-02 | 2023-10-18 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cftr mediated diseases |
JP6146990B2 (ja) * | 2012-11-16 | 2017-06-14 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化されたcftr増強物質 |
WO2014078842A1 (en) | 2012-11-19 | 2014-05-22 | Concert Pharmaceuticals, Inc. | Deuterated cftr potentiators |
CN109364075B (zh) * | 2012-11-21 | 2021-10-29 | 顶点制药(欧洲)有限公司 | 氘化cftr增效剂 |
CN103044263A (zh) * | 2013-01-14 | 2013-04-17 | 中国药科大学 | 一种治疗囊性纤维化药物的中间体的制备方法 |
US9550735B2 (en) | 2013-01-31 | 2017-01-24 | Glenmark Pharmaceuticals Limited | Process for the preparation of ivacaftor and solvates thereof |
US9573902B2 (en) | 2013-02-15 | 2017-02-21 | Laurus Labs Private Ltd. | Process for the preparation of Ivacaftor and its intermediates |
JP6545148B2 (ja) | 2013-03-13 | 2019-07-17 | フラットリー ディスカバリー ラブ,エルエルシー | ピリダジノン化合物及び嚢胞性線維症の治療のための方法 |
EP2970468B1 (en) | 2013-03-13 | 2021-07-07 | Novartis AG | Notch2 binding molecules for treating respiratory diseases |
WO2014167327A1 (en) * | 2013-04-09 | 2014-10-16 | Cresset Biomolecular Discovery Ltd | The treatment of inflammatory disorders |
EP2815749A1 (en) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
CA2918814C (en) * | 2013-07-23 | 2021-10-12 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives and use thereof as factor xia/plasma |
EP3049393A4 (en) * | 2013-09-25 | 2017-06-21 | Valorisation-Recherche, Limited Partnership | Inhibitors of polynucleotide repeat-associated rna foci and uses thereof |
ES2865600T3 (es) | 2013-11-12 | 2021-10-15 | Vertex Pharma | Proceso de preparación de composiciones farmacéuticas para el tratamiento de enfermedades mediadas por CFTR |
CA2927661A1 (en) | 2013-11-13 | 2015-05-21 | Apotex Inc. | Solid forms of ivacaftor and processes for the preparation thereof |
WO2015128882A2 (en) * | 2014-02-27 | 2015-09-03 | Msn Laboratories Private Limited | Crystalline forms of n-(2,4-di-tert-butyl-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide and process for the preparation thereof |
WO2015160787A1 (en) | 2014-04-15 | 2015-10-22 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
EP2932966A1 (en) | 2014-04-16 | 2015-10-21 | Novartis AG | Gamma secretase inhibitors for treating respiratory diseases |
ES2682105T3 (es) | 2014-05-12 | 2018-09-18 | Verona Pharma Plc | Nuevo tratamiento |
WO2015176168A1 (en) * | 2014-05-23 | 2015-11-26 | UNIVERSITé LAVAL | Fluorescent nanosensors and uses thereof |
BR112016027383A8 (pt) | 2014-06-03 | 2021-07-20 | Novartis Ag | derivados de naftiridinadiona, seus usos, composição farmacêutica e combinação |
AR101196A1 (es) | 2014-07-16 | 2016-11-30 | Gruenenthal Gmbh | Compuestos de pirimidina sustituidos |
AR101198A1 (es) | 2014-07-16 | 2016-11-30 | Gruenenthal Gmbh | Pirimidinas 2,5-sustituidas como inhibidores de pde4b |
TWI687409B (zh) * | 2014-08-28 | 2020-03-11 | 日商大塚製藥股份有限公司 | 稠合雜環化合物 |
CN112279808B (zh) | 2014-10-06 | 2024-03-08 | 弗特克斯药品有限公司 | 囊性纤维化跨膜转导调节因子调节剂 |
CN107250113B (zh) | 2014-10-07 | 2019-03-29 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调节蛋白的调节剂的共晶 |
WO2016069891A1 (en) | 2014-10-31 | 2016-05-06 | Abbvie Inc. | Substituted tetrahydropyrans and method of use |
MX2017005931A (es) | 2014-11-07 | 2017-06-30 | Senomyx Inc | Acidos 4-amino-5- (ciclohexiloxi) quinolina-3-carboxilicos sustituidos como modificadores del sabor dulce. |
JP6494757B2 (ja) | 2014-11-18 | 2019-04-03 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | ハイスループット試験高速液体クロマトグラフィーを行うプロセス |
JP6887389B2 (ja) | 2015-02-11 | 2021-06-16 | アイカーン スクール オブ メディスン アット マウント サイナイIcahn School of Medicine at Mt. Sinai | ニーマン・ピック病および他のリソソーム蓄積障害のためのnpc1のベンゼンスルホンアミド上方制御剤 |
GB201504878D0 (en) | 2015-03-23 | 2015-05-06 | Algipharma As | Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion |
US10336703B2 (en) | 2015-05-12 | 2019-07-02 | Council Of Scientific And Industrial Research | Process for the synthesis of ivacaftor and related compounds |
WO2016196303A1 (en) | 2015-05-29 | 2016-12-08 | Emory University | 3-(phenyl)-n-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide compounds for the management of cftr protein mediated diseases |
WO2016196297A1 (en) | 2015-05-29 | 2016-12-08 | Emory University | 2-amino-n'-benzylideneacetohydrazides and derivatives for the management of cftr protein mediated diseases |
PE20180457A1 (es) | 2015-06-02 | 2018-03-05 | Abbvie Sarl | Piridinas sustituidas y metodo de uso |
US9840513B2 (en) | 2015-07-16 | 2017-12-12 | Abbvie S.Á.R.L. | Substituted tricyclics and method of use |
CN105130872B (zh) * | 2015-08-25 | 2018-01-30 | 江西师范大学 | 一种3位三氟甲基取代吲哚的制备方法 |
EP3344249B1 (en) | 2015-09-02 | 2020-10-28 | Laurus Labs Limited | Processes for the preparation of ivacaftor |
MA42954A (fr) | 2015-09-25 | 2018-08-01 | Vertex Pharmaceuticals Europe Ltd | Potentialisateurs cftr deutérés |
WO2017060779A1 (en) | 2015-10-06 | 2017-04-13 | Optimus Drugs (P) Limited | Industrial process for making an ivacaftor and its intermediates |
GB201517639D0 (en) | 2015-10-06 | 2015-11-18 | Algipharma As | Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract |
AU2016333856C1 (en) | 2015-10-09 | 2021-12-09 | AbbVie Global Enterprises Ltd. | N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use |
CA3001094A1 (en) | 2015-10-09 | 2017-04-13 | Abbvie S.A.R.L. | Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and their use |
CN108602816A (zh) | 2015-10-09 | 2018-09-28 | 艾伯维公司 | 用于治疗囊性纤维化的新颖化合物 |
US10758530B2 (en) | 2016-02-19 | 2020-09-01 | Phoenix Molecular Designs | Carboxamide derivatives useful as rsk inhibitors |
HUP1600270A2 (hu) | 2016-04-25 | 2017-10-30 | Druggability Tech Ip Holdco Ltd | Ivacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadott készítményei |
HUP1600271A2 (hu) | 2016-04-25 | 2017-10-30 | Druggability Tech Ip Holdco Ltd | Ivacaftor és Lumacaftor sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadható készítményei |
HUP1600269A2 (hu) | 2016-04-25 | 2017-10-30 | Druggability Tech Ip Holdco Ltd | Lumacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyászati készítményei |
US10206915B2 (en) | 2016-04-25 | 2019-02-19 | Druggability Technologies Ip Holdco Limited | Complexes of Ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
US10383865B2 (en) | 2016-04-25 | 2019-08-20 | Druggability Technologies Ip Holdco Limited | Pharmaceutical combination composition comprising complex formulations of Ivacaftor and Lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them |
US10376501B2 (en) | 2016-04-25 | 2019-08-13 | Druggability Technologies Ip Holdco Limited | Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
EP3448842A1 (en) | 2016-04-26 | 2019-03-06 | AbbVie S.À.R.L. | Modulators of cystic fibrosis transmembrane conductance regulator protein |
EP3464243A2 (en) | 2016-05-30 | 2019-04-10 | Council of Scientific and Industrial Research | An improved process for the synthesis of ivacaftor |
US10138227B2 (en) | 2016-06-03 | 2018-11-27 | Abbvie S.Á.R.L. | Heteroaryl substituted pyridines and methods of use |
CN105884628B (zh) * | 2016-06-06 | 2018-06-29 | 上海工程技术大学 | 2,4-二叔丁基-5-氨基酚的制备方法 |
CN106046376B (zh) * | 2016-06-16 | 2019-02-22 | 上海交通大学 | 含叔丁基b′b2型三胺单体和其超支化聚酰亚胺及制备方法 |
PE20191147A1 (es) | 2016-09-30 | 2019-09-02 | Vertex Pharma | Modulador de regulador de conductancia de transmembrana de fibrosis quistica, composiciones farmaceuticas, metodos de tratamiento y proceso para producir el modulador |
US10399940B2 (en) | 2016-10-07 | 2019-09-03 | Abbvie S.Á.R.L. | Substituted pyrrolidines and methods of use |
US9981910B2 (en) | 2016-10-07 | 2018-05-29 | Abbvie S.Á.R.L. | Substituted pyrrolidines and methods of use |
JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
UY37513A (es) | 2016-12-09 | 2018-07-31 | Vertex Pharma | Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador |
WO2018116185A1 (en) | 2016-12-20 | 2018-06-28 | AbbVie S.à.r.l. | Deuterated cftr modulators and methods of use |
JP2017105824A (ja) * | 2017-02-10 | 2017-06-15 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化されたcftr増強物質 |
TW201831471A (zh) | 2017-02-24 | 2018-09-01 | 盧森堡商艾伯維公司 | 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法 |
CN108623561A (zh) * | 2017-03-24 | 2018-10-09 | 中国海洋大学 | 一种制备哌尼诺酸化合物的方法 |
US20180280349A1 (en) | 2017-03-28 | 2018-10-04 | Vertex Pharmaceuticals Incorporated | Methods of treating cystic fibrosis in patients with residual function mutations |
BR112019025801A2 (pt) | 2017-06-08 | 2020-07-07 | Vertex Pharmaceuticals Incorporated | métodos de tratamento para fibrose cística |
EP3654969A1 (en) | 2017-07-17 | 2020-05-27 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
AU2018309043B2 (en) | 2017-08-02 | 2022-03-31 | Vertex Pharmaceuticals Incorporated | Processes for preparing pyrrolidine compounds |
EP3664822A4 (en) * | 2017-08-04 | 2021-07-07 | Axial Therapeutics, Inc. | MICROBIAL INDUCED AMYLOID FORMATION INHIBITORS |
US10988454B2 (en) | 2017-09-14 | 2021-04-27 | Abbvie Overseas S.À.R.L. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
US20210369749A1 (en) * | 2017-10-06 | 2021-12-02 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
WO2019079760A1 (en) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS |
BR112020010335A2 (pt) | 2017-12-01 | 2020-11-10 | Vertex Pharmaceuticals Incorporated | processos para produzir moduladores de regulador de condutância de transmembrana de fibrose cística |
KR20200097293A (ko) | 2017-12-08 | 2020-08-18 | 버텍스 파마슈티칼스 인코포레이티드 | 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법 |
KR20200110650A (ko) | 2017-12-13 | 2020-09-24 | 프락시스 바이오테크 엘엘씨 | 통합된 스트레스 반응 경로의 억제제 |
WO2019136314A1 (en) | 2018-01-05 | 2019-07-11 | The Curators Of The University Of Missouri | Compounds and methods for treatment of cystic fibrosis |
WO2019148195A2 (en) | 2018-01-29 | 2019-08-01 | Ohio State Innovation Foundation | Cyclic peptidyl inhibitors of cal-pdz binding domain |
TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
SG11202006614VA (en) | 2018-02-15 | 2020-08-28 | Vertex Pharma | Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them |
WO2019193062A1 (en) | 2018-04-03 | 2019-10-10 | Abbvie S.Á.R.L | Substituted pyrrolidines and their use |
EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
EP3801522A4 (en) | 2018-06-05 | 2022-06-01 | Praxis Biotech LLC | INTEGRATED STRESS RESPONSE PATHWAY INHIBITORS |
JP6654223B2 (ja) * | 2018-08-13 | 2020-02-26 | バーテックス ファーマシューティカルズ (ヨーロッパ) リミテッド | 重水素化されたcftr増強物質 |
CN111056950A (zh) * | 2018-10-16 | 2020-04-24 | 广东石油化工学院 | 一种制备3’,4’-二氯-2-氨基联苯的方法 |
JP7402467B2 (ja) | 2019-01-30 | 2023-12-21 | 慶應義塾 | パーキンソン病治療薬 |
CZ309045B6 (cs) * | 2019-04-08 | 2021-12-22 | Univerzita Palackého v Olomouci | Způsob přípravy 6-amino-2,3-difluorbenzonitrilu |
WO2020214921A1 (en) | 2019-04-17 | 2020-10-22 | Vertex Pharmaceuticals Incorporated | Solid forms of modulators of cftr |
WO2020212898A1 (en) * | 2019-04-18 | 2020-10-22 | Callidus Research Laboratories Pvt Limited | Pharmaceutical oral liquid solution of ivacaftor |
EP3747882A1 (en) | 2019-06-03 | 2020-12-09 | AbbVie Overseas S.à r.l. | Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
JP2022536663A (ja) * | 2019-06-12 | 2022-08-18 | プラクシス バイオテック エルエルシー | 統合的ストレス応答経路のモジュレーター |
WO2021011327A1 (en) | 2019-07-12 | 2021-01-21 | Orphomed, Inc. | Compound for treating cystic fibrosis |
TW202115092A (zh) | 2019-08-14 | 2021-04-16 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
JP2022545359A (ja) | 2019-08-14 | 2022-10-27 | バーテックス ファーマシューティカルズ インコーポレイテッド | 嚢胞性線維症膜コンダクタンス制御因子モジュレーター |
TW202120517A (zh) | 2019-08-14 | 2021-06-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
JP2022544383A (ja) | 2019-08-14 | 2022-10-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Cftrモジュレータの結晶形態 |
CN114981243A (zh) | 2019-11-12 | 2022-08-30 | 健赞公司 | 用于治疗由cftr活性缺陷介导的疾病和病状的6元杂芳基氨基磺酰胺 |
WO2021113809A1 (en) | 2019-12-05 | 2021-06-10 | Genzyme Corporation | Arylamides and methods of use thereof |
WO2021113806A1 (en) | 2019-12-05 | 2021-06-10 | Genzyme Corporation | Arylamides and methods of use thereof |
CN111012782B (zh) * | 2019-12-27 | 2023-08-04 | 郑州大学第一附属医院 | 一种g蛋白偶联受体gpr84抑制剂及其应用 |
WO2022013360A1 (en) | 2020-07-17 | 2022-01-20 | Synthon B.V. | Pharmaceutical composition comprising ivacaftor |
CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
WO2022036060A1 (en) | 2020-08-13 | 2022-02-17 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
MX2023001993A (es) | 2020-08-20 | 2023-02-27 | Univ Leland Stanford Junior | Metodos para tratar enfermedades respiratorias caracterizados por hipersecrecion de mucosidad. |
EP3970718A1 (en) | 2020-09-18 | 2022-03-23 | Charité - Universitätsmedizin Berlin | New medical use of cystic fibrosis transmembrane conductance regulator (cftr) modulators |
EP4225750A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2022076621A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
IL301757A (en) | 2020-10-07 | 2023-05-01 | Vertex Pharma | Cystic fibrosis transmembrane regulator conductance modulators |
MX2023004073A (es) | 2020-10-07 | 2023-07-05 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica. |
WO2022076626A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
AU2021358063A1 (en) | 2020-10-07 | 2023-05-18 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2022076628A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
EP4225762A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
EP4225761A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2022076627A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US20220213041A1 (en) | 2021-01-06 | 2022-07-07 | AbbVie Global Enterprises Ltd. | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use |
EP4274828A1 (en) | 2021-01-06 | 2023-11-15 | AbbVie Global Enterprises Ltd. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
CN113149881B (zh) * | 2021-03-04 | 2022-07-19 | 宁波大学 | 一种手性衍生化试剂及其制备方法和应用 |
CN113461612B (zh) * | 2021-07-20 | 2022-10-14 | 上海应用技术大学 | 一种喹诺酮类端锚聚合酶2抑制剂及其制备方法和应用 |
CN113683590B (zh) * | 2021-08-23 | 2023-05-09 | 南京大学 | 具有阿扎菲酮结构的偶联试剂及其在制备多肽、蛋白质偶联物中的应用 |
WO2023034992A1 (en) | 2021-09-03 | 2023-03-09 | Genzyme Corporation | Indole compounds and methods of use |
WO2023034946A1 (en) | 2021-09-03 | 2023-03-09 | Genzyme Corporation | Indole compounds and uses thereof in the treatement of cystic fibrosis |
WO2023044556A1 (en) * | 2021-09-24 | 2023-03-30 | Enveric Biosciences Canada Inc. | Aminated psilocybin derivatives and methods of using |
WO2023150237A1 (en) | 2022-02-03 | 2023-08-10 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
WO2023150236A1 (en) | 2022-02-03 | 2023-08-10 | Vertex Pharmaceuticals Incorporated | Methods of preparing and crystalline forms of (6a,12a)-17-amino-12-methyl-6,15-bis(trifluoromethyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadeca-1(18),2,4,14,16-pentaen-6-ol |
WO2023154291A1 (en) | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2023154519A1 (en) * | 2022-02-14 | 2023-08-17 | Accent Therapeutics, Inc. | Inhibitors of rna helicase dhx9 and uses thereof |
WO2023196429A1 (en) | 2022-04-06 | 2023-10-12 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2023224931A1 (en) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
WO2023224924A1 (en) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Solid forms of a macrocyclic compounds as cftr modulators and their preparation |
WO2024031081A1 (en) | 2022-08-04 | 2024-02-08 | Vertex Pharmaceuticals Incorporated | Compositions for the treatment of cftr-mediated diseases |
EP4321162A1 (en) | 2022-08-08 | 2024-02-14 | Consejo Superior de Investigaciones Científicas (CSIC) | Antiviral agents for the treatment of infections by coronaviruses |
CN115353478B (zh) * | 2022-08-17 | 2023-10-27 | 南京工业大学 | 一种吲哚类化合物的制备方法 |
EP4335434A1 (en) | 2022-08-17 | 2024-03-13 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical compositions comprising ivacaftor |
WO2024054845A1 (en) | 2022-09-07 | 2024-03-14 | Sionna Therapeutics | Macrocycic compounds, compositions, and methods of using thereof |
WO2024054840A1 (en) | 2022-09-07 | 2024-03-14 | Sionna Therapeutics | Macrocyclic compounds, compositions, and methods of using thereof |
WO2024054851A1 (en) | 2022-09-07 | 2024-03-14 | Sionna Therapeutics | Macrocyclic compounds, compositions and methods of using thereof |
WO2024056798A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Macrocyclic cftr modulators |
WO2024056791A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Combination of macrocyclic cftr modulators with cftr correctors and / or cftr potentiators |
CN115961298A (zh) * | 2022-12-31 | 2023-04-14 | 广西师范大学 | 一种电化学介导乙烯基苯胺与醇合成2,3-二烷氧基取代吲哚啉化合物、合成方法及应用 |
CN116082163B (zh) * | 2023-01-06 | 2023-10-13 | 河北凡克新材料有限公司 | 一种3’,4’-二氟-2’-胺基联苯的制备方法 |
Family Cites Families (333)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE279887C (ja) | ||||
US574471A (en) * | 1897-01-05 | Corn-harvester | ||
FR960299A (ja) | 1950-04-15 | |||
US3830797A (en) | 1964-11-05 | 1974-08-20 | Pennwalt Corp | Tertiary-aliphatic-alpha-(peracyl)azo compounds |
US5874424A (en) | 1995-12-20 | 1999-02-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
US3524858A (en) * | 1967-05-18 | 1970-08-18 | Warner Lambert Pharmaceutical | 1,4 - dihydro-1-substituted alkyl-6,7-methylenedioxy - 4 - oxoquinoline-3-carboxylic acid |
US3443940A (en) * | 1967-07-24 | 1969-05-13 | Polaroid Corp | Diffusion transfer employing ringclosure to release color-providing material for transfer |
DE1908548A1 (de) | 1968-02-29 | 1970-11-05 | Warner Lambert Co | Chinolinderivate |
BE757639A (fr) * | 1969-10-17 | 1971-04-16 | Roussel Uclaf | Nouveaux derives de la cephalosporine et procede de preparation |
AT308173B (de) | 1970-02-03 | 1973-06-25 | Maurer Friedrich Soehne | Überbrückungsvorrichtung für Dehnungsfugen in Brücken od. dgl. |
JPS5146719B2 (ja) * | 1972-06-29 | 1976-12-10 | ||
US4110355A (en) * | 1972-12-26 | 1978-08-29 | Polaroid Corporation | Anthraquinone compounds useful in photographic processes |
US3931145A (en) | 1972-12-27 | 1976-01-06 | Gaf Corporation | Keto-amido containing phenylazophenyl dyestuffs |
GB1433774A (en) * | 1973-02-26 | 1976-04-28 | Allen & Hanburys Ltd | Heterocyclic compounds apparatus for conveying articles |
GB1433151A (en) * | 1973-04-05 | 1976-04-22 | Allen & Hanburys Ltd | Benzo-ij-quinolizines |
FR2281761A1 (fr) | 1974-08-13 | 1976-03-12 | Roussel Uclaf | Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament |
FR2324304A2 (fr) | 1975-09-22 | 1977-04-15 | Roussel Uclaf | Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament |
FR2340092A2 (fr) | 1976-02-09 | 1977-09-02 | Roussel Uclaf | Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament |
FR2340735A1 (fr) | 1976-02-11 | 1977-09-09 | Roussel Uclaf | Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament |
DE2861226D1 (en) | 1977-06-28 | 1981-12-10 | Univ Strathclyde | A pharmaceutical composition for tropical diseases |
DE2808070A1 (de) | 1978-02-24 | 1979-08-30 | Bayer Ag | Verfahren zur herstellung von 4-pyridon-3-carbonsaeuren und/oder deren derivaten |
FR2443467A1 (fr) * | 1978-12-08 | 1980-07-04 | Roussel Uclaf | Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament |
US4312870A (en) | 1979-06-21 | 1982-01-26 | Ciba-Geigy Corporation | Pyrazoloquinolines |
JPS56110612A (en) | 1980-02-08 | 1981-09-01 | Yamanouchi Pharmaceut Co Ltd | Readily disintegrable and absorbable compression molded article of slightly soluble drug |
US4390541A (en) * | 1980-12-19 | 1983-06-28 | Lilly Industries Limited | Quinolone derivatives and their use in a method of controlling an immediate hypersensitivity disease |
HU190796B (en) | 1981-06-12 | 1986-11-28 | Roussel Uclaf,Fr | Process for producing n-dihydrothiazolyl-3-quinoline-carboxamide derivatives |
FR2509728A1 (fr) | 1981-07-17 | 1983-01-21 | Roussel Uclaf | Nouveaux derives de la quinoleine, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant |
US5281612A (en) | 1982-09-09 | 1994-01-25 | Warner-Lambert Company | Naphthyridine antibacterial agents |
US4638067A (en) | 1982-09-09 | 1987-01-20 | Warner-Lambert Co. | Antibacterial agents |
FR2537140B1 (fr) | 1982-12-07 | 1986-07-18 | Roussel Uclaf | Nouveaux derives de la 4-hydroxy-3-quinoleine carboxamide, leur sels, procede de preparation, application a titre de medicaments, et compositions les renfermant |
SU1360584A3 (ru) | 1983-08-12 | 1987-12-15 | Варнер-Ламберт Компани (Фирма) | Способ получени нафтиридинхинолин-или бензоксазинкарбоновых кислот или их фармацевтически допустимых солей присоединени кислоты |
US4845105A (en) | 1984-10-30 | 1989-07-04 | Roussel Uclaf | 4-OH-quinoline carboxylic acid amides having analgesic and anti-inflammatory activity |
DE3571251D1 (en) * | 1984-11-01 | 1989-08-03 | Ciba Geigy Ag | Coatings stabilized against the action of light |
JPH0620877B2 (ja) * | 1986-04-23 | 1994-03-23 | トヨタ自動車株式会社 | 車両の加速スリツプ制御方法 |
US4687539A (en) | 1986-10-29 | 1987-08-18 | International Business Machines Corp. | End point detection and control of laser induced dry chemical etching |
DE3702393A1 (de) | 1987-01-28 | 1988-08-11 | Bayer Ag | 8-cyano-1-cyclopropyl-1,4-dihydro-4-oxo- 3-chinolincarbonsaeuren, verfahren zu ihrer herstellung und diese enthaltende antibakterielle mittel |
DD279887A1 (de) | 1987-07-03 | 1990-06-20 | Inst Pharmakologische Forschun | Verfahren zur herstellung von d-alpha-(4(1h)-1,5-naphthyridon-3-carboxamido)-benzylpenicillin und anderen beta-lactamantibiotika |
US4777252A (en) | 1987-08-13 | 1988-10-11 | E. R. Squibb & Sons, Inc. | 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines |
DE3827253A1 (de) | 1987-08-20 | 1989-03-02 | Sandoz Ag | Ester und amide von cyclischen carbonsaeuren und cyclischen alkoholen und aminen sowie verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen |
DE3731516A1 (de) * | 1987-09-18 | 1989-03-30 | Bayer Ag | N-aryl-stickstoffheterocyclen |
DE3811341A1 (de) | 1987-10-09 | 1989-04-27 | Bayer Ag | In 7-stellung c-verknuepfte chinolon- und 1,8-naphthyridin-4-on-carbonsaeure und ein verfahren zu ihrer herstellung |
JPH01116431A (ja) | 1987-10-30 | 1989-05-09 | Saginomiya Seisakusho Inc | 複合力試験機における相互干渉補正方法 |
US4786644A (en) * | 1987-11-27 | 1988-11-22 | Hoechst-Roussel Pharmaceuticals Inc. | 1-aryl-3-quinolinecarboxamide |
DE3808117A1 (de) | 1988-03-11 | 1989-09-21 | Bayer Ag | N-cyclopropylaniline und deren verwendung in verfahren zur herstellung von 1-cyclopropyl-chinoloncarbonsaeuren und deren derivaten |
DE3808118A1 (de) | 1988-03-11 | 1989-09-21 | Bayer Ag | Verfahren zur herstellung von 1-cyclopropyl-chinoloncarbonsaeuren und deren derivaten |
DE3816119A1 (de) | 1988-05-11 | 1989-11-23 | Bayer Ag | 7-substituierte chinolon- und naphthyridoncarbonsaeure-derivate |
JPH01287066A (ja) | 1988-05-13 | 1989-11-17 | Fujimoto Seiyaku Kk | 新規なアントラニル酸誘導体 |
JPH01168920U (ja) | 1988-05-18 | 1989-11-29 | ||
DK273689A (da) | 1988-06-06 | 1989-12-07 | Sanofi Sa | 4-amino-3-carboxyquinoliner og -naphthyridiner, fremgangsmaade til deres fremstilling og anvendelse deraf i laegemidler |
DE3827221A1 (de) * | 1988-08-11 | 1990-02-15 | Bayer Ag | Substituierte n-phenyl-stickstoff- bzw. stickstoff-schwefel-heterocyclen, verfahren sowie entsprechende heterocyclische phenolderivate, phenyliso(thio)cyanate und -carbamate als zwischenprodukte zu ihrer herstellung, ihre verwendung in herbiziden und pflanzenwuchsregulierenden mitteln |
US5491139A (en) | 1988-10-24 | 1996-02-13 | The Procter & Gamble Company | Antimicrobial quinolonyl lactams |
DE3903799A1 (de) | 1989-02-09 | 1990-08-16 | Bayer Ag | N-aryl-stickstoffheterocyclen |
JPH0334977A (ja) | 1989-06-29 | 1991-02-14 | Yoshitomi Pharmaceut Ind Ltd | イミダゾリルベンゾラクタム化合物 |
DE3924052A1 (de) * | 1989-07-21 | 1991-01-24 | Bayer Ag | N- (indol-6-yl)-heterocyclen |
GB2236751B (en) | 1989-10-14 | 1993-04-28 | Wyeth John & Brother Ltd | Heterocyclic compounds |
US5254135A (en) | 1989-10-20 | 1993-10-19 | L'oreal | Methods for dyeing keratinous fibres with aminoindoles, compositions and devices for use |
FR2659552B2 (fr) * | 1989-10-20 | 1994-11-04 | Oreal | Procede de teinture des fibres keratiniques avec des aminoindoles, composition et dispositif de mise en óoeuvre. |
LU87611A1 (fr) * | 1989-10-20 | 1991-05-07 | Oreal | Composition tinctoriale pour fibres keratiniques contenant des precurseurs de colorants par oxydation et des coupleurs amino indoliques,procedes de teinture mettant en oeuvre ces compositions et composes nouveaux |
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
FR2662713B1 (fr) * | 1990-05-29 | 1994-04-08 | Oreal | Procede de teinture de fibres keratiniques avec un aminoindole associe a un derive quinonique. |
DE4017516A1 (de) | 1990-05-31 | 1991-12-05 | Wella Ag | Oxidationshaarfaerbemittel mit einem gehalt an 3-aminophenol-derivaten, verfahren zum oxidativen faerben von haaren sowie neue 3-aminophenol-derivate |
US5409503A (en) | 1990-05-31 | 1995-04-25 | Wella Aktiengesellschaft | Oxidation hair dye with a content of 5-aminophenyl derivatives, process for oxidative dyeing of hair and new 5-aminophenol derivatives |
DE4026530A1 (de) | 1990-08-22 | 1992-02-27 | Basf Ag | Synergistische mittel zur regulierung des pflanzenwachstums |
AU8448491A (en) | 1990-09-07 | 1992-03-30 | Schering Corporation | Antiviral compounds and antihypertensive compounds |
JPH07110853B2 (ja) | 1990-09-07 | 1995-11-29 | シェリング・コーポレーション | 抗ウイルス化合物および抗高血圧化合物 |
US5175151A (en) | 1990-09-07 | 1992-12-29 | Schering Corporation | Antiviral compounds and antihypertensive compounds |
JPH04171521A (ja) | 1990-11-05 | 1992-06-18 | Fujitsu Ltd | タッチパネル |
IL100917A0 (en) | 1991-02-16 | 1992-11-15 | Fisons Plc | Pyridinone and pyrimidinone derivatives,their preparation and pharmaceutical compositions containing them |
CA2065106A1 (en) | 1991-04-04 | 1992-10-05 | Junichi Fukawa | Silver halide photographic light-sensitive material and photographic product for film-making process |
FR2675380A1 (fr) * | 1991-04-18 | 1992-10-23 | Oreal | Procede de teinture des fibres keratiniques avec des aminoindoles, a ph basique, compositions mises en óoeuvre et nouveaux composes. |
US5938792A (en) * | 1991-04-18 | 1999-08-17 | L'oreal | Process for dyeing keratinous fibers with aminoindoles and oxidation dye precursors at basic Ph's and dyeing agents |
GB9108547D0 (en) | 1991-04-22 | 1991-06-05 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
CA2075154A1 (en) | 1991-08-06 | 1993-02-07 | Neelakantan Balasubramanian | Peptide aldehydes as antithrombotic agents |
JPH05345780A (ja) | 1991-12-24 | 1993-12-27 | Kumiai Chem Ind Co Ltd | ピリミジンまたはトリアジン誘導体及び除草剤 |
JPH05184185A (ja) | 1991-12-27 | 1993-07-23 | Copal Electron Co Ltd | Dcブラシレスモータ速度制御方法 |
JPH05231760A (ja) | 1992-02-24 | 1993-09-07 | Sanyo Electric Co Ltd | 冷蔵庫の温度制御装置 |
ATE195530T1 (de) | 1992-05-20 | 2000-09-15 | Merck & Co Inc | 17-ether und thioether von 4-aza-steroiden |
CA2135173A1 (en) | 1992-05-20 | 1993-11-25 | Bruce E. Witzel | Ester derivatives of 4-aza-steroids |
JPH0672979A (ja) | 1992-06-08 | 1994-03-15 | Hiroyoshi Hidaka | アミノベンジル誘導体 |
US5352690A (en) | 1992-07-01 | 1994-10-04 | Eli Lilly And Company | 1,2,4-trioxygenated benzene derivatives useful as leukotriene antagonists |
ES2103479T3 (es) | 1992-07-10 | 1997-09-16 | Glaxo Lab Sa | Derivados de anilida. |
US5322847A (en) | 1992-11-05 | 1994-06-21 | Pfizer Inc. | Azabenzimidazoles in the treatment of asthma, arthritis and related diseases |
JPH06171521A (ja) | 1992-12-07 | 1994-06-21 | Mitsubishi Motors Corp | 油圧パワーステアリング装置 |
WO1994014797A1 (en) | 1992-12-23 | 1994-07-07 | Smithkline Beecham Corporation | Quinoline compounds and the treatment of leucotriene related diseases therewith |
JPH06278180A (ja) | 1993-03-26 | 1994-10-04 | Mitsubishi Heavy Ind Ltd | 型盤開限度ストッパ装置 |
US5750754A (en) | 1993-03-29 | 1998-05-12 | Zeneca Limited | Heterocyclic compounds |
JP3760474B2 (ja) | 1993-04-22 | 2006-03-29 | ダイキン工業株式会社 | 電気エネルギーを発生させる方法、装置およびそれに用いるn−f結合を有する化合物 |
US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
JPH0733729A (ja) | 1993-07-26 | 1995-02-03 | Kirin Brewery Co Ltd | N−シアノ−n′−置換−アリールカルボキシイミダミド化合物の製造法 |
JPH0782498A (ja) | 1993-09-17 | 1995-03-28 | Fuji Photo Film Co Ltd | ビスアゾ化合物 |
GB9420590D0 (en) | 1993-10-22 | 1994-11-30 | Zeneca Ltd | Pyridazino quinoline compounds |
JPH07179407A (ja) | 1993-11-12 | 1995-07-18 | Green Cross Corp:The | 新規縮合環系化合物またはその塩、およびその医薬用途 |
JP3319838B2 (ja) | 1993-11-12 | 2002-09-03 | 本田技研工業株式会社 | 車両のトラクション制御装置 |
ES2132430T3 (es) | 1994-02-25 | 1999-08-16 | Aranda Lab Sa De Cv | Derivados de la quinolonilcarboxamidocefalosporina y composiciones farmaceuticas que los contienen. |
FR2720397B1 (fr) | 1994-05-24 | 1996-08-23 | Laphal Laboratoires Sa | Nouveaux oxathiolanes, leur procédé de préparation et les compositions pharmaceutiques qui en renferment. |
ITMI941099A1 (it) | 1994-05-27 | 1995-11-27 | Smithkline Beecham Farma | Derivati chinolinici |
ES2227769T3 (es) | 1994-05-27 | 2005-04-01 | Glaxosmithkline S.P.A. | Derivados de quinolina como antagonistas del receptor nk3 de taquiquinina. |
EP0705835A1 (de) | 1994-09-01 | 1996-04-10 | Ciba-Geigy Ag | Oxa- oder thiaaliphatisch überbrückte Chinoxalin-2,3-dione |
WO1996015099A1 (en) | 1994-11-09 | 1996-05-23 | Novo Nordisk A/S | Heterocyclic compounds, their preparation and use |
JP3556982B2 (ja) | 1994-12-15 | 2004-08-25 | 小島プレス工業株式会社 | ラゲ−ジトレイ |
AU4314196A (en) | 1994-12-21 | 1996-07-10 | Yamanouchi Pharmaceutical Co., Ltd. | Solid composition with improved solubility and absorbability |
GB9501567D0 (en) | 1995-01-26 | 1995-03-15 | Pharmacia Spa | Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
JPH08301849A (ja) | 1995-05-01 | 1996-11-19 | Takeda Chem Ind Ltd | ヘテロ環化合物およびその製造法 |
JPH0971534A (ja) | 1995-06-26 | 1997-03-18 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
DE19601142A1 (de) | 1995-07-13 | 1997-01-16 | Agfa Gevaert Ag | Verfahren zur Erzeugung eines farbigen Bildes |
AU695132B2 (en) | 1995-08-02 | 1998-08-06 | Darwin Discovery Limited | Quinolones and their therapeutic use |
ES2193252T3 (es) | 1995-08-02 | 2003-11-01 | Darwin Discovery Ltd | Quinolonas y su uso terapeutico. |
US5721474A (en) | 1995-08-11 | 1998-02-24 | Samsung Electronics Co., Ltd. | Method and apparatus for preventing excessive current flow in a motor |
DE19532235A1 (de) | 1995-08-31 | 1997-03-06 | Keppler Bernhard K Priv Doz Dr | An Phosphonsäuren gekoppelte antibakteriell wirksame Verbindungen zur Therapie von Infektionen im Bereich des Knochens |
WO1997014682A1 (en) | 1995-10-19 | 1997-04-24 | Takeda Chemical Industries, Ltd. | Quinoline derivatives as gnrh antagonists |
NZ325248A (en) * | 1995-12-23 | 1999-09-29 | Pfizer Res & Dev | Quinoline and quinazoline compounds useful in therapy |
AU710825B2 (en) * | 1996-02-21 | 1999-09-30 | Darwin Discovery Limited | Quinolones and their therapeutic use |
US6215016B1 (en) | 1996-03-27 | 2001-04-10 | Toray Industries, Inc. | Ketone derivatives and medical application thereof |
DE19615262A1 (de) | 1996-04-18 | 1997-10-23 | Bayer Ag | Heteroverknüpfte Phenylglycinolamide |
JP2000510866A (ja) | 1996-05-20 | 2000-08-22 | ダーウィン・ディスカバリー・リミテッド | Tnfとpde―ivのインヒビターとしてのキノリンスルホンアミド |
WO1997044036A1 (en) | 1996-05-20 | 1997-11-27 | Darwin Discovery Limited | Quinoline carboxamides as tnf inhibitors and as pde-iv inhibitors |
WO1997048694A1 (en) | 1996-06-20 | 1997-12-24 | Board Of Regents, The University Of Texas System | Compounds and methods for providing pharmacologically active preparations and uses thereof |
EP0918761B1 (en) | 1996-07-23 | 2003-05-02 | Neurogen Corporation | Certain amido- and amino-substituted benzylamine derivatives; a new class of neuropeptite y1 specific ligands |
GB9717576D0 (en) | 1997-08-19 | 1997-10-22 | Xenova Ltd | Pharmaceutical compounds |
US6069151A (en) | 1996-11-06 | 2000-05-30 | Darwin Discovery, Ltd. | Quinolines and their therapeutic use |
DE19651099A1 (de) | 1996-12-09 | 1998-06-10 | Consortium Elektrochem Ind | Mehrkomponentensystem zum Verändern, Abbau oder Bleichen von Lignin, ligninhaltigen Materialien oder ähnlichen Stoffen sowie Verfahren zu seiner Anwendung |
DE19654147A1 (de) * | 1996-12-23 | 1998-06-25 | Basf Ag | Verwendung von Aminoisothiazolen als Mikrobizide |
WO1998031226A1 (de) | 1997-01-15 | 1998-07-23 | Novartis Ag | Herbizides mittel |
US5948814A (en) | 1997-02-20 | 1999-09-07 | The Curators Of The University Of Missouri | Genistein for the treatment of cystic fibrosis |
ZA986594B (en) | 1997-07-25 | 1999-01-27 | Abbott Lab | Urokinase inhibitors |
US6258822B1 (en) | 1997-08-06 | 2001-07-10 | Abbott Laboratories | Urokinase inhibitors |
ATE364374T1 (de) | 1997-08-11 | 2007-07-15 | Pfizer Prod Inc | Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit |
DK0998272T3 (da) | 1997-08-26 | 2003-08-25 | Aventis Pharma Inc | Farmaceutisk præparat til kombinationen piperidinoalkanoldekongestivum |
US6429207B1 (en) | 1997-11-21 | 2002-08-06 | Nps Pharmaceuticals, Inc. | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases |
TR200002616T2 (tr) | 1997-12-22 | 2000-11-21 | Bayer Corporation | Simetrik ve simetrik olmayan sübstitüe edilmiş difenil üreler kullanılarak raf kinazın inhibe edilmesi |
WO1999046267A1 (en) | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
CN1300279A (zh) * | 1998-03-12 | 2001-06-20 | 诺沃挪第克公司 | 蛋白质酪氨酸磷酸酶的调节物 |
WO1999046237A1 (en) | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases |
KR20010041814A (ko) * | 1998-03-12 | 2001-05-25 | 온토젠 코포레이션 | 단백질 티로신 포스파타제(ptpases)의 조절제 |
DE19818614A1 (de) | 1998-04-20 | 1999-10-21 | Basf Ag | Neue substituierte Amide, deren Herstellung und Anwendung |
JP2000016982A (ja) | 1998-06-30 | 2000-01-18 | Kumiai Chem Ind Co Ltd | キノリン誘導体及びこれを有効成分とする除草剤 |
US6133285A (en) | 1998-07-15 | 2000-10-17 | Active Biotech Ab | Quinoline derivatives |
BR9912571A (pt) | 1998-07-28 | 2001-11-20 | Nihon Nohyaku Co Ltd | Derivado de diamida de ácido dicarboxìlicoheterocìclico fundido, herbicida, e, processo paraa utilização de um herbicida |
SK285438B6 (sk) | 1998-08-03 | 2007-01-04 | Applied Research Systems Ars Holding N. V. | Spôsob prípravy (1H)-benzo[c]chinolizín-3-ových derivátov |
US7001770B1 (en) | 1998-10-15 | 2006-02-21 | Canji, Inc. | Calpain inhibitors and their applications |
FR2786483B1 (fr) | 1998-12-01 | 2001-02-16 | Rhodia Chimie Sa | Procede de preparation de 4-hydroxyquinoleines et/ou formes tautomeres |
US6248739B1 (en) | 1999-01-08 | 2001-06-19 | Pharmacia & Upjohn Company | Quinolinecarboxamides as antiviral agents |
US6248736B1 (en) | 1999-01-08 | 2001-06-19 | Pharmacia & Upjohn Company | 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents |
DK1033364T3 (da) | 1999-03-01 | 2005-06-06 | Pfizer Prod Inc | Cyanholdige oxamidsyrer og -derivater som thyroideareceptorligander |
JP2000256358A (ja) * | 1999-03-10 | 2000-09-19 | Yamanouchi Pharmaceut Co Ltd | ピラゾール誘導体 |
MXPA01011173A (es) * | 1999-05-06 | 2002-04-24 | Neurogen Corp | 4-0x0-quinolin-3-carboxamidas sustituidas: ligandos del receptor cerebro de gaba. |
CO5200844A1 (es) | 1999-09-17 | 2002-09-27 | Novartis Ag | Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes |
PL199781B1 (pl) | 1999-10-25 | 2008-10-31 | Active Biotech Ab | Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania |
SE0002320D0 (sv) | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
DE19951671A1 (de) | 1999-10-27 | 2001-05-03 | Basf Ag | 2-(4,6-Dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionssäure-Natriumsalz und seine Verwendung als Endothelinantagonist |
ATE312820T1 (de) * | 1999-10-28 | 2005-12-15 | Trine Pharmaceuticals Inc | Pumpeninhibitoren zur freisetzung von medikamenten |
JP2001199965A (ja) * | 1999-11-08 | 2001-07-24 | Sankyo Co Ltd | 含窒素複素環誘導体 |
WO2001034570A1 (fr) * | 1999-11-08 | 2001-05-17 | Sankyo Company, Limited | Derives heterocycliques azotes |
UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
DOP2000000107A (es) | 1999-12-01 | 2002-09-16 | Agouron Pharmaceutical Inc | Compuestos, composiciones y metodos para estimular el crecimiento y alongamiento de las neuronas |
JP2003519146A (ja) * | 1999-12-23 | 2003-06-17 | アストラゼネカ・アクチエボラーグ | 痛みの処置のための方法および組成物 |
JP2001233859A (ja) | 2000-02-23 | 2001-08-28 | Yamanouchi Pharmaceut Co Ltd | 抗ヘリコバクター・ヒ゜ロリ化合物の新規製造法及びその中間体 |
US6413958B2 (en) * | 2000-03-21 | 2002-07-02 | Pharmacia & Upjohn Company | 4-hydroxy-1,8-naphthyridine-3-carboxamides as antiviral agents |
GB0011409D0 (en) | 2000-05-11 | 2000-06-28 | Smithkline Beecham Plc | Novel compounds |
JP4949590B2 (ja) | 2000-05-17 | 2012-06-13 | シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト | アニリン化合物の製造方法 |
US6800297B2 (en) | 2000-06-15 | 2004-10-05 | Acusphere, Inc. | Porous COX-2 inhibitor matrices and methods of manufacture thereof |
WO2002003938A1 (en) * | 2000-06-29 | 2002-01-17 | Clairol Incorporated | Iodo-containing organic couplers for use in oxidative hair dyeing |
KR100866820B1 (ko) | 2000-07-13 | 2008-11-04 | 다케다 야쿠힌 고교 가부시키가이샤 | 지질 풍부 플라크 퇴축제 |
US7112594B2 (en) | 2000-08-09 | 2006-09-26 | Mitsubishi Pharma Corporation | Fused bicyclic amide compounds and medicinal use thereof |
AU2002212102A1 (en) | 2000-11-08 | 2002-05-21 | Aeromatic-Fielder Ag | A process for production of particles for pharmaceutical compositions having increased bioavailability |
JP2002212179A (ja) | 2001-01-15 | 2002-07-31 | Wakunaga Pharmaceut Co Ltd | 新規アニリド誘導体又はその塩及びこれを含有する医薬 |
GB2372986A (en) | 2001-01-17 | 2002-09-11 | Xenova Ltd | 2-oxo, 4-hydroxy pyrroles and quinolines |
GB0102687D0 (en) * | 2001-02-02 | 2001-03-21 | Pharmacia & Upjohn Spa | Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them |
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
DE10108271A1 (de) | 2001-02-21 | 2002-08-22 | Schering Ag | Chinolin-, Isochinolin- und Phthalazinderivate als Antagonisten des Gonadotropin freisetzenden Hormons |
US6515001B2 (en) | 2001-03-05 | 2003-02-04 | Chemokine Therapeutic Corporation | IL-8 receptor ligands-drugs for inflammatory and autoimmune diseases |
DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
CZ305838B6 (cs) * | 2001-03-29 | 2016-04-06 | Eli Lilly And Company | N-(2-arylethyl)benzylaminy jako antagonisté receptoru 5-HT6 |
US6878713B2 (en) | 2001-04-25 | 2005-04-12 | Wockhardt Limited | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments |
JP2002322054A (ja) | 2001-04-26 | 2002-11-08 | Dai Ichi Seiyaku Co Ltd | 薬剤排出ポンプ阻害薬 |
JP2002322154A (ja) | 2001-04-27 | 2002-11-08 | Dai Ichi Seiyaku Co Ltd | 抗真菌化合物 |
JP2002326935A (ja) * | 2001-05-07 | 2002-11-15 | Sankyo Co Ltd | 含窒素複素環誘導体を含有する医薬 |
CA2448076A1 (en) | 2001-05-24 | 2002-11-28 | Masahiko Hayakawa | 3-quinoline-2-(1h)-ylideneindolin-2-one derivatives |
JP2003012667A (ja) | 2001-06-26 | 2003-01-15 | Rrf Kenkyusho:Kk | キノリンカルボキサミド骨格を有する抗菌剤 |
JP4047658B2 (ja) | 2001-09-18 | 2008-02-13 | 株式会社リコー | 単層型電子写真感光体、電子写真方法、電子写真装置、及び電子写真装置用プロセスカートリッジ |
AU2002349882A1 (en) | 2001-09-21 | 2003-04-01 | Case Western Reserve University | Q4n2neg2 enhances cftr activity |
MXPA04002537A (es) | 2001-10-12 | 2004-05-31 | Warner Lambert Co | Alquinos como inhibidores de metaloproteinasa de matriz. |
TW200300349A (en) * | 2001-11-19 | 2003-06-01 | Sankyo Co | A 4-oxoqinoline derivative |
JP2005519876A (ja) | 2001-11-27 | 2005-07-07 | メルク エンド カムパニー インコーポレーテッド | 2−アミノキノリン化合物 |
PL373484A1 (en) | 2001-12-10 | 2005-09-05 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
WO2003063821A2 (en) | 2002-02-01 | 2003-08-07 | Pfizer Products Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles |
JP2003238413A (ja) | 2002-02-14 | 2003-08-27 | Kyowa Hakko Kogyo Co Ltd | ステロイドスルファターゼ阻害剤 |
DE10211413A1 (de) | 2002-03-15 | 2003-09-25 | Wella Ag | Quinolinium-Salze enthaltende Färbemittel |
US6930131B2 (en) | 2002-04-10 | 2005-08-16 | Wyeth | Aryl substituted 3-ethoxy phenyl trifluoromethane sulfonamides for the treatment of non-insulin dependent diabetes mellitus (NIDDM) |
US7718663B2 (en) | 2002-04-26 | 2010-05-18 | Nippon Shinyaku Co., Ltd. | Quinazoline derivatives and medicaments |
US7037913B2 (en) | 2002-05-01 | 2006-05-02 | Bristol-Myers Squibb Company | Bicyclo 4.4.0 antiviral derivatives |
DE60326341D1 (de) | 2002-05-14 | 2009-04-09 | Xenova Ltd | Verfahren zur herstellung von anthranilsäurederivat-hydrat |
US7355047B2 (en) | 2002-05-14 | 2008-04-08 | The Regents Of The University Of California | Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof |
DE10222968A1 (de) * | 2002-05-23 | 2003-12-04 | Basf Ag | Verfahren zur Herstellung von Isocyanaten |
SE0201669D0 (sv) | 2002-06-03 | 2002-06-03 | Pharmacia Ab | New formulation and use thereof |
EP1542699A4 (en) | 2002-07-15 | 2009-03-25 | Myriad Genetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF |
US20040033959A1 (en) | 2002-07-19 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
AU2003249532A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 4-hydroxyquinoline derivatives as matrix metalloproteinase inhibitors |
TWI314041B (en) | 2002-10-21 | 2009-09-01 | Sankyo Agro Co Ltd | Quinolyl-3-carboxamide compound |
PE20040844A1 (es) * | 2002-11-26 | 2004-12-30 | Novartis Ag | Acidos fenilaceticos y derivados como inhibidores de la cox-2 |
JP2004189738A (ja) * | 2002-11-29 | 2004-07-08 | Nippon Nohyaku Co Ltd | 置換アニリド誘導体、その中間体及び農園芸用薬剤並びにその使用方法 |
US20050113423A1 (en) | 2003-03-12 | 2005-05-26 | Vangoor Frederick F. | Modulators of ATP-binding cassette transporters |
WO2004105779A2 (en) | 2003-05-27 | 2004-12-09 | Cesare Montecucco | Green tea and oplyphenol inhibitors of bacterial proteases |
ATE440825T1 (de) | 2003-06-06 | 2009-09-15 | Vertex Pharma | Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern |
CA2530352A1 (en) | 2003-07-24 | 2005-02-03 | Astellas Pharma Inc. | Quinolone derivative or salt thereof |
CN1191252C (zh) | 2003-08-11 | 2005-03-02 | 中国药科大学 | 3-位取代的喹诺酮衍生物及其在药学上的应用 |
MXPA06002567A (es) | 2003-09-06 | 2006-09-04 | Vertex Pharma | Moduladores de transportadores con casete de union de atp. |
US20050059035A1 (en) | 2003-09-09 | 2005-03-17 | Quest Diagnostics Incorporated | Methods and compositions for the amplification of mutations in the diagnosis of cystic fibrosis |
SI3395339T1 (sl) | 2003-09-12 | 2019-08-30 | Amgen, Inc, | Hitrotopna formulacija, ki vsebuje cinakalcet HCL |
US7223759B2 (en) | 2003-09-15 | 2007-05-29 | Anadys Pharmaceuticals, Inc. | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds |
RU2006115602A (ru) | 2003-10-08 | 2007-11-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Модуляторы переносчиков атф-связывающих кассет |
KR101118930B1 (ko) | 2003-11-14 | 2012-03-14 | 아지노모토 가부시키가이샤 | 페닐알라닌 유도체의 고체 분산체 또는 고체 분산체 의약제제 |
EP1682127B1 (en) | 2003-11-14 | 2009-07-29 | Vertex Pharmaceuticals Incorporated | Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters |
US20050208095A1 (en) | 2003-11-20 | 2005-09-22 | Angiotech International Ag | Polymer compositions and methods for their use |
CA2548281C (en) | 2003-12-09 | 2013-11-12 | Medcrystalforms, Llc | Method of preparation of mixed phase co-crystals with active agents |
WO2005075435A1 (en) | 2004-01-30 | 2005-08-18 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
US20050186261A1 (en) | 2004-01-30 | 2005-08-25 | Angiotech International Ag | Compositions and methods for treating contracture |
US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
WO2005094805A1 (ja) * | 2004-04-01 | 2005-10-13 | Institute Of Medicinal Molecular Design. Inc. | イミン誘導体及びアミド誘導体 |
JP2006206612A (ja) | 2004-05-27 | 2006-08-10 | Ono Pharmaceut Co Ltd | 固形製剤用組成物 |
US7939558B2 (en) | 2004-06-04 | 2011-05-10 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof |
NZ587547A (en) * | 2004-06-24 | 2012-09-28 | Vertex Pharma | Modulators of ATP-Binding Cassette Transporters |
US20140343098A1 (en) | 2004-06-24 | 2014-11-20 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
US8354427B2 (en) * | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
JP2008505124A (ja) | 2004-07-02 | 2008-02-21 | アドバンシス ファーマスーティカル コーポレイション | パルス送達用錠剤 |
BRPI0515527A (pt) | 2004-09-21 | 2008-07-29 | Thomas Joseph Lally | composição de biomaterial de múltiplos propósitos |
WO2006099256A2 (en) | 2005-03-11 | 2006-09-21 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
CA2600869A1 (en) | 2005-03-18 | 2006-09-28 | The Regents Of The University Of California | Compounds having activity in correcting mutant-cftr processing and uses thereof |
KR20080005575A (ko) | 2005-04-28 | 2008-01-14 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 안정화 조성물 |
US8822451B2 (en) | 2005-05-24 | 2014-09-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
NZ566208A (en) | 2005-08-11 | 2010-09-30 | Vertex Pharma | 2-Thiazolamide derivatives as modulators of cystic fibrosis transmembrane conductance regulators |
ZA200802172B (en) | 2005-08-11 | 2009-06-24 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
EP1933831A2 (en) | 2005-10-06 | 2008-06-25 | Vertex Pharmaceuticals, Inc. | Modulators of atp-binding cassette transporters |
SI2404919T1 (sl) | 2005-11-08 | 2013-12-31 | Vertex Pharmaceuticals Incorporated | Heterocikliäśna spojina uporabna kot modulator za prenaĺ alce z atp-vezavno kaseto |
US20120232059A1 (en) | 2005-11-08 | 2012-09-13 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette Transporters |
US20080057047A1 (en) | 2005-11-29 | 2008-03-06 | Benedikt Sas | Use of bacillus amyloliquefaciens PB6 for the prophylaxis or treatment of gastrointestinal and immuno-related diseases |
WO2007067559A2 (en) | 2005-12-06 | 2007-06-14 | Regents Of The University Of Minnesota | Antibacterial agents |
US20090105272A1 (en) | 2005-12-24 | 2009-04-23 | Grootenhuis Peter D J | Prodrugs of modulators of ABC transporters |
EP1974212A1 (en) | 2005-12-27 | 2008-10-01 | Vertex Pharmaceuticals Incorporated | Compounds useful in cftr assays and methods therewith |
EP1978939A2 (en) | 2005-12-27 | 2008-10-15 | Jubilant Organosys Limited | Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxine |
PL3219705T3 (pl) | 2005-12-28 | 2020-08-10 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne amorficznych postaci n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4-dihydro-4-oksochinolino-3-karboksyamidu |
ES2398319T3 (es) | 2005-12-28 | 2013-03-15 | Vertex Pharmaceuticals Incorporated | Derivados de 1-(benzo[D][1,3]dioxol-5-il)-N-(fenil)ciclopropano-carboxamida y compuestos relacionados como moduladores de transportadores de casetes de unión a ATP para el tratamiento de la fibrosis quística |
US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
CN101443314B (zh) | 2006-03-13 | 2014-04-09 | 杏林制药株式会社 | 作为gsk-3抑制剂的氨基喹诺酮类 |
WO2007106957A1 (en) | 2006-03-21 | 2007-09-27 | Laboratoires Smb S.A. | Multiple units controlled-release floating dosage forms |
SI3091011T1 (en) | 2006-04-07 | 2018-06-29 | Vertex Pharmaceuticals Incorporated | Modulators of ATP conveyor belt conveyors |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
MX2008013532A (es) | 2006-04-20 | 2009-01-15 | Janssen Pharmaceutica Nv | Inhibidores de c-fms cinasa. |
ATE534383T1 (de) * | 2006-05-12 | 2011-12-15 | Vertex Pharma | Zusammensetzungen aus n-ä2,4-bis(1,1- dimethylethyl)-5-hydroxyphenylü-1,4-dihydro-4- oxochinolin-3-carboxamid |
TW200824723A (en) | 2006-09-12 | 2008-06-16 | Glaxo Group Ltd | Pharmaceutical composition |
NZ576642A (en) | 2006-11-03 | 2011-11-25 | Vertex Pharma | Azaindole derivatives as cftr modulators |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
WO2008083130A2 (en) | 2006-12-26 | 2008-07-10 | Dr. Reddy's Laboratories Limited | Amorphous and crystalline form a of carvedilol phosphate |
AU2008251504B2 (en) | 2007-05-09 | 2013-07-18 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
WO2008147952A1 (en) | 2007-05-25 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2009023509A2 (en) | 2007-08-09 | 2009-02-19 | Vertex Pharmaceuticals Incorporated | Therapeutic combinations useful in treating cftr related diseases |
NZ583420A (en) | 2007-08-24 | 2012-06-29 | Vertex Pharma | Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis |
EP2201010B1 (en) * | 2007-09-14 | 2013-11-06 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
CN101918366A (zh) * | 2007-09-14 | 2010-12-15 | 弗特克斯药品有限公司 | N-[2,4-双(1,1-二甲基乙基)-5-羟基苯基]-1,4-二氢-4-氧代喹啉-3-甲酰胺的固体形式 |
EP2217572B1 (en) | 2007-11-16 | 2013-11-06 | Vertex Pharmaceuticals Incorporated | Isoquinoline modulators of atp-binding cassette transporters |
US20100036130A1 (en) | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
EA201070699A1 (ru) | 2007-12-07 | 2011-02-28 | Вертекс Фармасьютикалз Инкорпорейтед | Композиции 3-(6-(1-2,2-дифторбензо[d][1,3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты |
DK2639222T3 (en) | 2007-12-07 | 2016-10-03 | Vertex Pharma | Methods for preparing cycloalkylcarboxamido-pyridinbenzoesyrer |
KR20150063170A (ko) | 2007-12-07 | 2015-06-08 | 버텍스 파마슈티칼스 인코포레이티드 | 3-(6-(1-(2,2-디플루오로벤조[d][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태 |
CN101925603B (zh) | 2007-12-13 | 2013-12-04 | 沃泰克斯药物股份有限公司 | 囊性纤维化跨膜通道调节因子的调节剂 |
NZ602030A (en) | 2008-02-28 | 2014-02-28 | Vertex Pharma | Heteroaryl derivatives as cftr modulators |
CN103951614A (zh) | 2008-03-31 | 2014-07-30 | 沃泰克斯药物股份有限公司 | 作为cftr调节剂的吡啶基衍生物 |
EP3842037A1 (en) | 2008-08-13 | 2021-06-30 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
US20100256184A1 (en) | 2008-08-13 | 2010-10-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
WO2010025126A1 (en) | 2008-08-26 | 2010-03-04 | Cystic Fibrosis Foundation Therapeutics, Inc. | Rapidly disintegrating tablets comprising lipase, amylase, and protease |
AR073709A1 (es) | 2008-09-29 | 2010-11-24 | Vertex Pharma | Unidades de dosis de acido 3-(6-(1-(2,2-difluorobenzeno (d) (1,3) dioxol-5-il) ciclopropancarboxamido)-3-metilpiridin-2-il) benzoico |
AR074060A1 (es) | 2008-10-23 | 2010-12-22 | Vertex Pharma | Moduladores del regulador de conductancia transmembrana de la fibrosis quistica |
AU2009308241B2 (en) | 2008-10-23 | 2016-01-07 | Vertex Pharmaceuticals Incorporated | Solid forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl) phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide |
NZ592687A (en) | 2008-10-23 | 2013-04-26 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
US20110257223A1 (en) | 2008-10-23 | 2011-10-20 | Vertex Pharmaceuticals Incorporated | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator |
ES2532753T3 (es) | 2008-11-06 | 2015-03-31 | Vertex Pharmaceuticals Incorporated | Moduladores de transportadores del casete de unión a ATP |
UA104876C2 (uk) | 2008-11-06 | 2014-03-25 | Вертекс Фармасьютікалз Інкорпорейтед | Модулятори atф-зв'язувальних касетних транспортерів |
US8321242B1 (en) * | 2008-12-02 | 2012-11-27 | Fox Chase Bank | Personalized time release messaging |
US8367660B2 (en) | 2008-12-30 | 2013-02-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
NZ624460A (en) | 2009-03-20 | 2015-12-24 | Vertex Pharma | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
PL2408749T3 (pl) | 2009-03-20 | 2018-11-30 | Vertex Pharmaceuticals Incorporated | Modulatory transbłonowego regulatora przewodnictwa mukowiscydozy |
JP5793496B2 (ja) | 2009-09-17 | 2015-10-14 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | アザ二環式化合物を調製するプロセス |
EP2490687A1 (en) | 2009-10-22 | 2012-08-29 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
CN102648182A (zh) | 2009-10-23 | 2012-08-22 | 沃泰克斯药物股份有限公司 | 用于制备囊性纤维化跨膜传导调节因子的调节剂的方法 |
RU2568608C2 (ru) | 2009-10-23 | 2015-11-20 | Вертекс Фармасьютикалз Инкорпорейтед | Твердые формы n-(4-(7-азабицикло[2.2.1]гептан-7-ил)-2-(трифторметил)фенил)-4-оксо-5-(трифторметил)-1,4-дигидрохинолин-3-карбоксамида |
CN103180298A (zh) | 2010-03-19 | 2013-06-26 | 沃泰克斯药物股份有限公司 | N-[2,4-双(1,1-二甲基乙基)-5-羟基苯基]-1,4-二氢-4-氧代喹啉-3-甲酰胺的固体形式 |
AU2011230508B2 (en) | 2010-03-25 | 2016-04-28 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihyderoxypropyl)-6-fluoro-2- (1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
HUE056525T2 (hu) | 2010-04-07 | 2022-02-28 | Vertex Pharma | 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)ciklopropánkarboxamido)-3-metilpiridin-2-il)benzoesav gyógyszerészeti készítményei és azok adagolása |
RU2579370C2 (ru) | 2010-04-07 | 2016-04-10 | Вертекс Фармасьютикалз Инкорпорейтед | Твердые формы 3-(2, 2-дифторбензо[d][1, 3] диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты |
EP2560651A1 (en) | 2010-04-22 | 2013-02-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
EP2560650A1 (en) * | 2010-04-22 | 2013-02-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
NZ603042A (en) | 2010-04-22 | 2015-02-27 | Vertex Pharma | Pharmaceutical compositions comprising cftr modulators and administrations thereof |
MX353408B (es) | 2010-04-22 | 2018-01-11 | Vertex Pharma | Proceso para producir compuestos de cicloalquilcarboxamido-indol. |
US20110288122A1 (en) | 2010-05-20 | 2011-11-24 | Vertex Pharmaceuticals Incorporated | Pharmaceutical Compositions and Administrations Thereof |
AR081920A1 (es) | 2010-05-20 | 2012-10-31 | Vertex Pharma | Procesos de produccion de moduladores del regulador de conductancia transmembrana de fibrosis quistica |
US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
FR2961171B1 (fr) | 2010-06-10 | 2013-03-08 | Messier Bugatti | Aeronef equipe d'un dispositif de deplacement autonome. |
US20120164080A1 (en) | 2010-06-24 | 2012-06-28 | Meritage Pharma, Inc. | Methods of treatment for esophageal inflammation |
BR112013004443A8 (pt) | 2010-08-23 | 2018-01-02 | Vertex Pharma | composições farmacêuticas de (r)-1-(2,2-difluorbenzo[d] [1,3]dioxol-5-il)-n-(1-(2,3-di-hidróxipropil)-6-flúor-2-(1-hidróxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropano carboxamida e administração das mesmas |
EP2608775A2 (en) | 2010-08-27 | 2013-07-03 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
CN102487499B (zh) * | 2010-12-01 | 2015-05-27 | 华为技术有限公司 | 隧道重定向的方法及互通功能实体 |
US8802700B2 (en) * | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
EP2773349A1 (en) | 2011-11-02 | 2014-09-10 | Vertex Pharmaceuticals Incorporated | Use of (n- [2, 4 -bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl]- 1, 4 - dihydro - 4 - oxoquinoline - 3 - carboxamide) for treating cftr mediated diseases |
US20140127901A1 (en) | 2012-11-08 | 2014-05-08 | Taiwan Semiconductor Manufacturing Company, Ltd. | Low-k damage free integration scheme for copper interconnects |
RU2640420C2 (ru) | 2011-11-08 | 2018-01-09 | Вертекс Фармасьютикалз Инкорпорейтед | Модуляторы транспортеров атф-связывающей кассеты |
SI2806859T1 (sl) | 2012-01-25 | 2019-11-29 | Vertex Pharma | Formulacije 3-(6-(1-(2.2-difluorobenzo(d)(1,3)dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzojske kisline |
IL265430B1 (en) | 2012-02-27 | 2024-04-01 | Vertex Pharma | Pharmaceutical preparations containing a solid dispersion of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide and uses thereof |
US8674108B2 (en) | 2012-04-20 | 2014-03-18 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
CA2874851A1 (en) | 2012-06-08 | 2013-12-12 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cftr-mediated disorders |
AU2013290444B2 (en) | 2012-07-16 | 2018-04-26 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof |
EP2914248B2 (en) | 2012-11-02 | 2023-10-18 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cftr mediated diseases |
US20140221424A1 (en) | 2013-01-30 | 2014-08-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for use in the treatment of cystic fibrosis |
ES2865600T3 (es) | 2013-11-12 | 2021-10-15 | Vertex Pharma | Proceso de preparación de composiciones farmacéuticas para el tratamiento de enfermedades mediadas por CFTR |
WO2015160787A1 (en) | 2014-04-15 | 2015-10-22 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
CN107250113B (zh) | 2014-10-07 | 2019-03-29 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调节蛋白的调节剂的共晶 |
JP6494757B2 (ja) | 2014-11-18 | 2019-04-03 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | ハイスループット試験高速液体クロマトグラフィーを行うプロセス |
WO2016086136A1 (en) | 2014-11-26 | 2016-06-02 | Catabasis Pharmaceuticals, Inc. | Fatty acid cysteamine conjugates of cftr modulators and their use in treating medical disorders |
MA41031A (fr) | 2014-11-26 | 2017-10-03 | Catabasis Pharmaceuticals Inc | Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie |
WO2016087665A2 (en) | 2014-12-05 | 2016-06-09 | Centre National De La Recherche Scientifique (Cnrs) | Compounds for treating cystic fibrosis |
EP3229791A4 (en) | 2014-12-09 | 2018-09-26 | Laurus Labs Limited | Novel polymorphs of ivacaftor, process for its preparation and pharmaceutical composition thereof |
CA2981495C (en) | 2015-03-31 | 2023-09-26 | Vertex Pharmaceuticals (Europe) Limited | Deuterated vx-661 |
GB201507926D0 (en) | 2015-05-08 | 2015-06-24 | Proqr Therapeutics N V | Improved treatments using oligonucleotides |
US10336703B2 (en) | 2015-05-12 | 2019-07-02 | Council Of Scientific And Industrial Research | Process for the synthesis of ivacaftor and related compounds |
UY36680A (es) | 2015-05-19 | 2016-12-30 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas como inhibidores de quinasa |
CA3021752A1 (en) | 2015-06-11 | 2016-12-15 | Aizant Drug Research Solutions Private Limited | Nanoparticulate ivacaftor formulations |
US20180280349A1 (en) | 2017-03-28 | 2018-10-04 | Vertex Pharmaceuticals Incorporated | Methods of treating cystic fibrosis in patients with residual function mutations |
-
2005
- 2005-06-24 NZ NZ587547A patent/NZ587547A/xx unknown
- 2005-06-24 RS RS20180153A patent/RS56873B1/sr unknown
- 2005-06-24 MX MX2007000095A patent/MX2007000095A/es active IP Right Grant
- 2005-06-24 ES ES05791060.6T patent/ES2534606T3/es active Active
- 2005-06-24 PL PL05791060T patent/PL1773816T3/pl unknown
- 2005-06-24 EP EP12152246.0A patent/EP2530075A3/en not_active Withdrawn
- 2005-06-24 CN CN201010243781.9A patent/CN101891680B/zh active Active
- 2005-06-24 MX MX2011005317A patent/MX341797B/es unknown
- 2005-06-24 NZ NZ587548A patent/NZ587548A/en unknown
- 2005-06-24 ME MEP-2015-33A patent/ME02156B/me unknown
- 2005-06-24 EP EP05791060.6A patent/EP1773816B1/en active Active
- 2005-06-24 CN CN2010102437753A patent/CN101935301B/zh active Active
- 2005-06-24 ME MEP-2018-44A patent/ME02970B/me unknown
- 2005-06-24 PT PT121522254T patent/PT2502911T/pt unknown
- 2005-06-24 MX MX2016011108A patent/MX365890B/es unknown
- 2005-06-24 NZ NZ598393A patent/NZ598393A/en unknown
- 2005-06-24 CN CN2005800280552A patent/CN101006076B/zh active Active
- 2005-06-24 DK DK12152224.7T patent/DK2489659T3/en active
- 2005-06-24 ES ES12152225.4T patent/ES2628026T3/es active Active
- 2005-06-24 JP JP2007518350A patent/JP4947658B2/ja active Active
- 2005-06-24 CA CA2571949A patent/CA2571949C/en active Active
- 2005-06-24 PL PL12152225T patent/PL2502911T3/pl unknown
- 2005-06-24 PT PT121522247T patent/PT2489659T/pt unknown
- 2005-06-24 ES ES12152224.7T patent/ES2656017T3/es active Active
- 2005-06-24 CN CN201510138309.1A patent/CN104788328B/zh active Active
- 2005-06-24 US US11/165,818 patent/US7495103B2/en active Active
- 2005-06-24 LT LTEP12152224.7T patent/LT2489659T/lt unknown
- 2005-06-24 LT LTEP12152225.4T patent/LT2502911T/lt unknown
- 2005-06-24 EP EP12152242.9A patent/EP2522659A3/en not_active Withdrawn
- 2005-06-24 CA CA2810655A patent/CA2810655C/en active Active
- 2005-06-24 DK DK12152225.4T patent/DK2502911T3/en active
- 2005-06-24 CN CN201310437141.5A patent/CN103641765B/zh active Active
- 2005-06-24 SI SI200532185T patent/SI2489659T1/en unknown
- 2005-06-24 DK DK05791060.6T patent/DK1773816T3/en active
- 2005-06-24 EP EP12152235.3A patent/EP2532650A3/en not_active Withdrawn
- 2005-06-24 CA CA2881078A patent/CA2881078C/en active Active
- 2005-06-24 ME MEP-2017-125A patent/ME02799B/me unknown
- 2005-06-24 WO PCT/US2005/022768 patent/WO2006002421A2/en active Application Filing
- 2005-06-24 BR BRPI0511321A patent/BRPI0511321B8/pt active IP Right Grant
- 2005-06-24 NZ NZ587549A patent/NZ587549A/xx unknown
- 2005-06-24 HU HUE12152225A patent/HUE032540T2/en unknown
- 2005-06-24 RS RS20170557A patent/RS56037B1/sr unknown
- 2005-06-24 EP EP12152237.9A patent/EP2502902A3/en not_active Withdrawn
- 2005-06-24 NZ NZ587551A patent/NZ587551A/en unknown
- 2005-06-24 ES ES17164829T patent/ES2786563T3/es active Active
- 2005-06-24 PL PL12152224T patent/PL2489659T3/pl unknown
- 2005-06-24 RS RS20150171A patent/RS53895B1/en unknown
- 2005-06-24 HU HUE12152224A patent/HUE036512T2/hu unknown
- 2005-06-24 BR BR122018075478A patent/BR122018075478B8/pt active Search and Examination
- 2005-06-24 AU AU2005258320A patent/AU2005258320B2/en active Active
- 2005-06-24 NZ NZ552543A patent/NZ552543A/en unknown
- 2005-06-24 CN CN201710740283.7A patent/CN107501099B/zh active Active
- 2005-06-24 EP EP12152224.7A patent/EP2489659B1/en active Active
- 2005-06-24 PT PT57910606T patent/PT1773816E/pt unknown
-
2006
- 2006-12-21 IL IL180224A patent/IL180224A/en active IP Right Grant
-
2007
- 2007-01-22 ZA ZA200700600A patent/ZA200700601B/xx unknown
- 2007-08-20 US US11/841,646 patent/US8829204B2/en active Active
- 2007-10-18 HK HK07111298.9A patent/HK1105970A1/xx unknown
-
2009
- 2009-01-09 US US12/351,401 patent/US8101767B2/en active Active
- 2009-01-09 US US12/351,447 patent/US8324242B2/en active Active
-
2010
- 2010-12-13 AU AU2010249302A patent/AU2010249302B2/en active Active
- 2010-12-14 AU AU2010251789A patent/AU2010251789C1/en active Active
- 2010-12-14 AU AU2010251787A patent/AU2010251787B2/en active Active
-
2011
- 2011-05-11 HK HK11104646.7A patent/HK1150602A1/xx unknown
- 2011-05-26 IL IL213158A patent/IL213158A/en active IP Right Grant
- 2011-05-26 IL IL213155A patent/IL213155B/en active IP Right Grant
- 2011-07-05 HK HK11106875.4A patent/HK1152707A1/xx unknown
- 2011-12-05 JP JP2011266326A patent/JP5654979B2/ja active Active
- 2011-12-05 JP JP2011266327A patent/JP5712117B2/ja active Active
- 2011-12-05 JP JP2011266325A patent/JP5762940B2/ja active Active
-
2012
- 2012-03-07 JP JP2012050845A patent/JP2012107069A/ja active Pending
- 2012-09-06 IL IL221828A patent/IL221828B/en active IP Right Grant
- 2012-09-06 IL IL221827A patent/IL221827A0/en unknown
- 2012-09-06 IL IL221826A patent/IL221826A0/en active IP Right Grant
- 2012-10-08 US US13/647,034 patent/US8629162B2/en active Active
-
2013
- 2013-08-15 US US13/968,274 patent/US20140187770A9/en not_active Abandoned
- 2013-10-25 US US14/063,785 patent/US8741925B2/en active Active
- 2013-12-19 US US14/135,204 patent/US20140155431A1/en not_active Abandoned
- 2013-12-19 US US14/135,065 patent/US20140163011A1/en not_active Abandoned
-
2014
- 2014-04-01 JP JP2014075501A patent/JP2014156468A/ja not_active Ceased
- 2014-07-30 US US14/446,870 patent/US9090619B2/en active Active
- 2014-10-06 US US14/507,170 patent/US20150031722A1/en not_active Abandoned
- 2014-11-11 US US14/538,282 patent/US20150315186A2/en not_active Abandoned
-
2015
- 2015-03-11 HR HRP20150277TT patent/HRP20150277T1/hr unknown
- 2015-03-13 CY CY20151100258T patent/CY1116116T1/el unknown
- 2015-07-02 HU HUS1500035C patent/HUS1500035I1/hu unknown
- 2015-07-02 LU LU92761C patent/LU92761I2/fr unknown
- 2015-07-03 LT LTPA2015028C patent/LTC1773816I2/lt unknown
- 2015-07-06 NL NL300748C patent/NL300748I1/nl unknown
- 2015-07-06 CY CY2015026C patent/CY2015026I1/el unknown
- 2015-07-06 JP JP2015135324A patent/JP2015172087A/ja not_active Withdrawn
-
2016
- 2016-01-21 HK HK16100649.7A patent/HK1212672A1/zh unknown
- 2016-02-29 US US15/056,313 patent/US20160318931A1/en not_active Abandoned
- 2016-05-01 IL IL245365A patent/IL245365A0/en unknown
- 2016-12-21 JP JP2016247687A patent/JP6285004B2/ja active Active
-
2017
- 2017-06-02 HR HRP20170847TT patent/HRP20170847T1/hr unknown
- 2017-06-15 CY CY20171100627T patent/CY1119100T1/el unknown
-
2018
- 2018-02-14 IL IL257540A patent/IL257540B/en active IP Right Grant
- 2018-02-19 HR HRP20180300TT patent/HRP20180300T1/hr unknown
- 2018-02-28 CY CY20181100246T patent/CY1119963T1/el unknown
- 2018-06-12 US US16/006,105 patent/US10662192B2/en active Active
-
2020
- 2020-03-16 IL IL273332A patent/IL273332A/en unknown